Cordis Corporation today announced it has received clearance from the Food and Drug Administration of its latest innovation in guiding catheters: the ADROIT
6F Guiding Catheter.
“The new ADROIT
Guiding Catheter, allows physicians to have more options for treating a wide range of challenging cases. It accommodates easier advancement of devices with its 0.072’ diameter, the largest inner diameter of any guiding catheter in the U.S., while providing better support and control at the same time. These features enhance treatment options for physicians, including the treatment of cases with complex lesions and those to be conducted using the radial approach,” said Celine Martin, Worldwide President, Cordis Corporation.
Catheter’s innovative hybrid braid wire technology not only enables the production of a guide catheter with the largest lumen size on the U.S. market today, it also facilitates better control and back up support. In addition, the new innovative design incorporating a flexible distal segment and soft longer tip allows atraumatic placement and stability. The ADROIT
Guiding Catheter provides a wide range of shapes, including extra back-up shapes and radial specific shapes to support treatment needs of various coronary anatomies.
“Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. We are excited for the launch of our new ADROIT
Guiding Catheter as it complements our guide catheter portfolio with its technological and design advances. We will continue to deliver innovative solutions that save lives and improve the quality of life for people around the world,” concluded Martin.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson Family of Companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with physicians worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at
(this site is intended for U.S. visitors).